Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Clinical trials

Treatment of HCV-infected patients with advanced kidney disease

Antiviral treatment options for HCV-infected patients with advanced kidney disease are limited because few clinical trials have tested the efficacy of antiviral drugs in this population. Now, a phase III trial of two pan-genotypic drugs demonstrates excellent viral clearance with minimal adverse events in HCV-infected patients with advanced kidney disease.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. 1

    Ladino, M., Pedraza, F. & Roth, D. Hepatitis C virus infection in chronic kidney disease. J. Am. Soc. Nephrol. 27, 2238–2246 (2016).

    CAS  Article  Google Scholar 

  2. 2

    Fabrizi, F., Dixit, V. & Messa, P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J. Viral Hepat. 19, 601–617 (2012).

    CAS  Article  Google Scholar 

  3. 3

    Molnar, M. Z. et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology 61, 1495–1502 (2015).

    CAS  Article  Google Scholar 

  4. 4

    Goodkin, D. A. et al. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin. J. Am. Soc. Nephrol. 12, 287–297 (2017).

    Article  Google Scholar 

  5. 5

    Gane, E. et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N. Engl. J. Med. 377, 1448–1455 (2017).

    CAS  Article  Google Scholar 

  6. 6

    Saxena, V. et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 36, 807–816 (2016).

    CAS  Article  Google Scholar 

  7. 7

    Roth, D. et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386, 1537–1545 (2015).

    CAS  Article  Google Scholar 

  8. 8

    Pockros, P. J. et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150, 1590–1598 (2016).

    CAS  Article  Google Scholar 

  9. 9

    Gane, E. et al. in AASLD The Liver Meeting abstract 935 (Boston, 2016).

    Google Scholar 

  10. 10

    Rodriguez, C. V. et al. in AASLD The Liver Meeting abstract 1946 (Boston, 2016).

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to David Roth.

Ethics declarations

Competing interests

M.L. declares no competing interests. D.R. is a consultant and is on the Scientific Advisory Boards for Merck & Co. and AbbVie.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ladino, M., Roth, D. Treatment of HCV-infected patients with advanced kidney disease. Nat Rev Nephrol 14, 6–8 (2018). https://doi.org/10.1038/nrneph.2017.161

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2017.161

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing